证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20260102 | | 特定对象调研 分析师会议 | | | --- | --- | --- | | 投资者关系活 | 业绩说明会 | 媒体采访 | | 动类别 | 路演活动 | 新闻发布会 | | | | 现场参观 | | | | 其他 | | 时间 2026 | 月 年 月 日 1 8 日、2026 1 9 | 年 | | 地点 | 宝莱特公司会议室 | | | 参与单位名称 | 陆伏崴 汇添富基金 毕宇倩 | 西部证券 | | | 张良龙 国泰基金 韩昊东 | 华创证券 | | | 陈峻 世传国际 陈玮 | 中邮证券 | | | 吴雨潇 和谐汇一 陈凯 | 睿郡资产 | | | 郭天敏、宋亚琴、林朝野、吴仁天、玥桐、刘子菲等参加国金 | 国金证券 | | | 证券"走进上市公司——宝莱特"活动的投资者。 | | | 上市公司接待 | 杨永兴 创新研究院院长助理 沈昭 | 董事会秘书 | | 人员姓名 | 李韵妮 证券事务专员 钟欣昊 | 证券事务代表 | | | | 一、公司介绍 | | ...

证券代码：300246 证券简称：宝莱特 广东宝莱特医用科技股份有限公司投资者关系活动记录表 编号：20260101 投资者关系活 动类别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 时间 2025 年 12 月 26 日 地点 宝莱特公司会议室 参与单位名称 东方证券 胡葵、罗帆、黄建秋、卢雯等参加东方证券"走进上市公司活 动——宝莱特"的投资者。 上市公司接待 人员姓名 董事会秘书 杨永兴 证券事务代表 李韵妮 证券事务专员 钟欣昊 投资者关系活 动主要内容介 绍 一、公司介绍 宝莱特成立于 1993 年，主营业务为医疗器械产品的研发、生产、销 售。公司作为中国最早一批研发制造医疗监护仪的民族企业，是国家发改 委授予的"国家多参数监护仪产业化基地"、工业和信息化部认定的"第八 批国家级制造业单项冠军企业"，目前公司的监护设备已覆盖数千家医疗 机构。 在生命信息与支持领域，公司的监护产品品类丰富，公司拥有一体式 监护仪、插件式监护仪和掌上监护仪三大系列产品，以及输注液泵、心电 图机、中央监护系统等院内医疗设备及配套产品，广泛应用于普通病房、 急诊室、ICU、CCU、 ...

内容概要：近年来，我国人口老龄化日益加剧，老年群体对于术后康复、慢性病治疗等方面的需求持续 增长，中频治疗仪在上述领域疗效显著，且随着康复医学的普及，骨科、神经科、产后康复等专科对中 频治疗仪的依赖度不断提升，此外，随着国民健康意识的不断增强，越来越多家庭会购置操作简便的中 频治疗仪用于日常疼痛缓解、亚健康调理等，带动我国中频治疗仪市场需求进一步增长，据比地招标网 数据显示，2024年我国中频治疗仪采购总量达6745台，同比增长37.26%；采购总金额达0.76亿元，同比 增长1.33%， 采购均价为1.13万元/台；2025年上半年我国中频治疗仪采购总量已完成2352台，采购总金 额已完成0.28亿元，其中，华南地区占比最大，高达30.47%，其次为华北地区和华东地区，分别占 20.14%和17.94%。 上市企业：翔宇医疗（688626）、倍益康（920199） 相关企业：宁波迈达医疗仪器有限公司、苏州好博医疗器械股份有限公司、三合正德（辽宁）医疗科技 有限公司、津准（三明）医学技术有限公司、中山市健怡康智能电子有限公司、郑州雅晨生物科技有限 公司、郑州名泰医疗器械有限公司、郑州静美医疗设备科技有限公司、 ...

内容概要：随着国民健康意识的提升，健康监测不再局限于生病后的就医检测，日常体检、慢性病管理 成为常态，这使得体检中心、社区卫生服务中心对尿液分析仪的需求持续增加，同时，人口老龄化加 剧，糖尿病、肾病等慢性病患者数量增多，这类患者需要长期进行尿液检测以监测病情，推动了医疗机 构和家庭对尿液分析仪的刚性需求，此外，养老机构、社区康养中心等新兴场景的兴起，也进一步拓展 了尿液分析仪的应用边界，据比地招标网数据显示，2024年我国尿液分析仪采购总量达1521台，同比增 长0.20%；采购均价为5.33万元/台；采购总金额达0.81亿元，与2023年基本持平，其中，华东地区占比 最大，高达33.7%，其次为华北地区和华中地区，分别占18.3%和14.4%。 上市企业：迪瑞医疗（300396）、迈瑞医疗（300760）、爱威科技（688067）、康泰医学（300869） 相关企业：桂林优利特电子集团有限公司、希森美康医用电子（上海）有限公司、深圳市美侨医疗科技 有限公司、艾康生物技术(杭州)有限公司、爱科来医疗科技（平湖）有限公司、安徽惠邦生物工程有限 公司、澳瑞（江西）科技有限公司、北京宝灵曼阳光科技有限公司、北京华晟 ...

Group 1: Company Overview and Market Position - The company is recognized as one of the earliest domestic enterprises in China to develop and manufacture medical monitoring devices, designated as a "National Multi-parameter Monitoring Instrument Industrialization Base" by the National Development and Reform Commission [1] - The company positions itself as a "critical care pioneer," focusing on high-end monitoring equipment primarily for ICU, anesthesia, and operating rooms, emphasizing high prices, added value, and technical barriers [1] - The P series plug-in monitor has won the "Red Dot Award" and features industry-leading anti-electrosurgical interference technology, intelligent early warning, high-end parameter integration analysis, and smart voice assistance [1] Group 2: Product Development and Innovation - The company plans to continue focusing on clinical needs, leveraging over 30 years of industry experience to enhance technological innovation and integrate smart solutions into product development [2] - New products will address core clinical pain points and feature "new quality" attributes, transitioning medical devices from "functional integration" to "intelligent decision-making" [2] Group 3: International Sales and Market Expansion - The company's blood dialysis products have entered overseas markets, with a 121.29% increase in overseas blood dialysis revenue in the first half of 2025, indicating positive growth [3] - The company aims to actively seize opportunities to expand its overseas blood dialysis market presence [3] Group 4: Regulatory Impact and Market Growth - The National Healthcare Security Administration's new pricing guidelines for blood dialysis services include monitoring items such as blood temperature and blood pressure, which the company's D800 series dialysis equipment can meet without additional modules [4] - The blood dialysis market has maintained a stable annual compound growth rate of approximately 12% over the past decade, with 1.027 million patients undergoing dialysis in 2024 [5] - The domestic blood dialysis equipment market saw sales growth in the first three quarters of 2025, driven by hospital operational recovery and centralized procurement [6] Group 5: New Product Launches and Financial Performance - Recent product launches include peritoneal dialysis machines, S series infusion pumps, electronic urine measuring devices, and telemetry monitors, enhancing the life information and support product line [6] - The subsidiary Suzhou Junkang reported revenue of 74.146 million yuan in the first three quarters of 2025, with plans to increase new product development and market expansion efforts [6]

Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the R&D, production, and sales of medical devices. It is recognized as a "National Multi-parameter Monitor Industrialization Base" and a "National Manufacturing Single Champion Enterprise" [1][2]. - The company’s monitoring equipment is utilized in thousands of medical institutions across China [1]. Product Categories - The company offers a diverse range of monitoring products, including integrated monitors, modular monitors, and handheld monitors, as well as infusion pumps, ECG machines, and central monitoring systems [2]. - In the renal medical field, Baolait has a complete industrial chain with eight consumable bases and a channel platform, providing products for blood dialysis and peritoneal dialysis [2]. Financial Performance - In the first half of 2025, the company achieved a revenue of CNY 523.44 million, a year-on-year decrease of 2.43%. However, the net profit attributable to shareholders increased by 152.22% to CNY 1.31 million [3]. - Total assets at the end of the reporting period were CNY 2.41 billion, a decrease of 3.66% from the beginning of the year [3]. R&D and Innovation - The company is focusing on clinical needs and technological innovation, aiming to integrate smart technology into product development to address core clinical pain points [4]. - Baolait's high-end monitoring products feature unique parameters and advanced technologies, enhancing their competitiveness in the market [5]. Market Demand and Opportunities - The number of blood dialysis patients in 2024 is projected to be 1.027 million, maintaining a compound annual growth rate of approximately 12% over the past decade [6]. - The company is actively expanding into the home dialysis market, particularly automated peritoneal dialysis, which has shown a growth rate of over 10% in recent years [7]. International Expansion - Baolait's blood dialysis products have begun to penetrate overseas markets, with a reported revenue growth of 121.29% in the first half of 2025 [8]. - The company is monitoring new policies related to blood dialysis and has developed products that meet the latest regulatory requirements [8]. New Product Launches - Recent product launches include peritoneal dialysis machines and smart monitoring devices, enhancing the company's product line in life information and support [8]. - The BioView C100 visual laryngoscope and S200 smart enteral nutrition pump were showcased at CMEF, featuring advanced imaging and safety features [8].

Market Overview and Growth Trends - The global medical pelvic traction device market is expanding, with an estimated market size of approximately 419 million USD in 2024, projected to reach 811 million USD by 2031, reflecting a compound annual growth rate (CAGR) of 10.0% from 2025 to 2031 [3][5]. Current Market Analysis - The medical pelvic traction device is gaining attention as an important rehabilitation and treatment tool, driven by an aging population and increasing awareness of skeletal health [6][10]. - Developed regions like Europe and North America dominate the market due to advanced healthcare systems and high acceptance of quality, intelligent traction devices. Meanwhile, the Asia-Pacific region, particularly countries like China and India, shows rapid growth potential due to economic development and a large patient base [6][10]. Product Types and Applications - Medical pelvic traction devices are categorized into manual, electric, and intelligent types. Manual devices are cost-effective, while electric devices offer stability and precision. Intelligent devices utilize advanced sensor technology and AI for personalized treatment [7][8]. - These devices are primarily used in orthopedics and rehabilitation, treating conditions such as pelvic fractures and lumbar disc herniation, and are also significant in gynecological treatments [9]. Market Influencing Factors - Key drivers include an aging population, advancements in medical technology, and rising health awareness among individuals, leading to increased demand for early diagnosis and treatment of pelvic diseases [10][11]. - Limitations include high prices of advanced devices and a shortage of skilled professionals to operate them [12][13]. - Opportunities lie in emerging markets and technological innovations, such as AI and big data integration [14][15]. - Challenges include intense market competition and stringent regulatory policies governing medical devices [16][17]. Future Development Trends - The future of medical pelvic traction devices is expected to focus on increased intelligence, portability, and remote medical capabilities, enhancing patient monitoring and treatment personalization [18][19][20].

Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established in 1993, focusing on the R&D, production, and sales of medical devices. It is recognized as a "National Multi-parameter Monitor Industrialization Base" and a "National Champion Enterprise" in manufacturing [1][2]. Product Range - The company offers a diverse range of monitoring products, including integrated monitors, modular monitors, and handheld monitors, as well as infusion pumps, ECG machines, and central monitoring systems, widely used in various medical settings [2]. - In the nephrology sector, Baolait has a comprehensive product line including hemodialysis machines, dialyzers, and peritoneal dialysis equipment, catering to both acute and chronic renal failure treatments [2]. Financial Performance - In Q1 2025, the company reported a revenue of ¥247,732,813.14, a decrease of 7.17% from ¥266,864,471.78 in the same period last year. However, net profit attributable to shareholders increased by 298.35% to ¥14,448,489.46 [3]. Policy Impact - The new "old-for-new" equipment policy positively impacts the company's monitoring device business by increasing demand for updated equipment in public hospitals and grassroots medical institutions [4][5]. - The policy is expected to enhance the procurement of mid-to-high-end monitoring devices and blood dialysis equipment, benefiting from potential financial subsidies or tax incentives [5]. Market Opportunities - The number of hemodialysis patients in 2024 is projected to be 1.027 million, maintaining a stable annual growth rate of approximately 12% over the past decade. The demand for hemodialysis is expected to remain consistent due to the stable incidence of chronic kidney disease [6]. - There is significant potential for domestic product replacement in the hemodialysis market, with increasing preference for local dialysis equipment [6]. International Expansion - The company has begun to expand its blood dialysis product sales overseas, although the scale remains small. Future efforts will focus on seizing opportunities in the international blood dialysis market [7]. Production Capacity - The production capacity for dialyzers is primarily located in Suzhou and Zhuhai, with additional facilities across various regions in China for other dialysis-related products [8]. Innovations in Peritoneal Dialysis - The company has developed the PD600 peritoneal dialysis device, which features remote monitoring capabilities and user-friendly design, enhancing patient convenience for home treatment [9][10]. R&D Focus - The company aims to innovate in the life information and support sector by integrating intelligent technology into product development, addressing clinical needs, and advancing the development of high-end monitoring devices and dialysis-related products [12].

Financial Performance - In Q1 2025, the company's operating revenue was 247,732,813.14 CNY, a decrease of 7.17% compared to the same period last year [5] - The net profit attributable to shareholders was 14,448,489.46 CNY, showing a significant increase of 298.35% year-on-year [5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 338,833.92 CNY, up 105.49% from the previous year [5] - Basic earnings per share reached 0.0546 CNY, reflecting a year-on-year growth of 298.54% [5] Market and Policy Impact - The implementation of new policies, such as the "Action Plan for Promoting Large-Scale Equipment Updates and Consumer Goods Replacement," is expected to positively impact the company's monitoring and dialysis product lines [2] - Increased demand for monitoring equipment is anticipated due to the policy-driven replacement of outdated devices in public hospitals and grassroots medical institutions [2] - The company aims to leverage these policies to enhance market share through product upgrades and expanded marketing efforts [2] Industry Trends - The blood dialysis market is projected to experience increased competition over the next 3-5 years, with market concentration expected to rise as leading companies consolidate their positions [3] - Technological advancements, such as home dialysis and smart monitoring, are anticipated to become new growth points, favoring early adopters [4] - The emergence of new markets, particularly in China and India, is expected to challenge international giants as local companies offer competitive pricing [4] Product Development and Innovation - The company plans to focus on developing intelligent medical devices that address clinical needs, with an emphasis on innovative solutions in the renal care sector [5] - New products, including a polypropylene blood dialysis device and specialized dialysis solutions, are set to be launched in 2024 [4] - The company is also working on a new CRRT machine that will integrate with its overall life support solutions [5] Revenue Breakdown - In 2024, the life information and support segment generated sales revenue of 243,502,800 CNY, accounting for approximately 23% of total revenue [6] - The renal medical segment achieved sales revenue of 804,300,500 CNY, representing about 76% of total revenue [6] Strategic Focus for 2025 - The company will concentrate on its two main business areas, aiming to capitalize on opportunities from medical infrastructure expansion and domestic product substitution [8] - Plans include enhancing the penetration of high-margin products in critical care and surgical anesthesia [8] - The company will also strengthen its supply chain and production efficiency to align with procurement policies and improve overall operational effectiveness [8]